Please wait while the formulary information is being retrieved.
ARRANON (NELARABINE)
- T-cell acute lymphoblastic leukemia
- T-cell lymphoblastic lymphoma
250 mg/50 mL intravenous solution
- Infuse 1,500 mg/m2 over 2 hour(s) by intravenous route on days 1, 3, and 5 of a 21-day treatment cycle
T-cell acute lymphoblastic leukemia
- Infuse 1,500 mg/m2 over 2 hour(s) by intravenous route on days 1, 3, and 5 of a 21-day treatment cycle
T-cell lymphoblastic lymphoma
- Infuse 1,500 mg/m2 over 2 hour(s) by intravenous route on days 1, 3, and 5 of a 21-day treatment cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- Nipent
- pentostatin
- Lactating mother
Contraindicated
- Altered mental status
- Demyelination
- Intrathecal injection of chemotherapeutic agent
- Peripheral neuropathy
- Pregnancy
- Radiation therapy of cranium
- Radiation therapy of vertebral column
- Seizure disorder
Severe
Moderate
- Anemia
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Hyperbilirubinemia
- Leukopenia
- Neutropenic disorder
- Severe hepatic disease
- Thrombocytopenic disorder
ARRANON (NELARABINE)
- T-cell acute lymphoblastic leukemia
- T-cell lymphoblastic lymphoma
- Abnormal hepatic function tests
- Anemia
- Hyperbilirubinemia
- Hypoalbuminemia
- Hypokalemia
- Leukopenia
- Neutropenic disorder
- Peripheral neuropathy
- Pleural effusions
- Thrombocytopenic disorder
- Arthralgias
- Constipation
- Cough
- Diarrhea
- Dizziness
- Drowsy
- Dyspnea
- Fatigue
- Fever
- Headache disorder
- Myalgias
- Nausea
- Peripheral sensory neuropathy
- Vomiting
More Frequent
Severe
Less Severe
- Dehydration
- Hypocalcemia
- Hypoglycemic disorder
- Hypomagnesemia
- Hypotension
- Infection
- Pneumonia
- Progressive multifocal leukoencephalopathy
- Seizure disorder
- Sinus tachycardia
- Abdominal distension
- Abdominal pain with cramps
- Acute confusion
- Anorexia
- Back pain
- Blurred vision
- Chest pain
- Chills
- Depression
- Dysesthesia
- Edema
- Epistaxis
- Gait abnormality
- General weakness
- Hyperglycemia
- Hypesthesia
- Insomnia
- Limb pain
- Pain
- Paresthesia
- Peripheral edema
- Peripheral motor neuropathy
- Petechiae
- Sinusitis
- Stomatitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute cerebellar syndrome
- Chemotherapy-induced hyperuricemia
- Demyelination
- Opportunistic fungal infection
- Paralysis
- Peripheral demyelinating neuropathy
- Rhabdomyolysis
- Severe infection
Less Severe
- Altered mental status
- Ataxia
- Dysgeusia
- Increased creatine kinase level
- Memory impairment
- Muscle weakness
- Tremor
- Wheezing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Nelarabine
Safety/efficacy not established. Increased risk of hematologic toxicity (e.g. anemia, leukopenia, neutropenia, and thrombocytopenia).
Increased risk of hematologic toxicity (e.g. anemia, leukopenia, neutropenia, and thrombocytopenia).
- 1 Day – 364 Days
- Safety/efficacy not established. Increased risk of hematologic toxicity (e.g. anemia, leukopenia, neutropenia, and thrombocytopenia).
- Increased risk of hematologic toxicity (e.g. anemia, leukopenia, neutropenia, and thrombocytopenia).
- 1 Years – 18 Years
- Safety/efficacy not established. Increased risk of hematologic toxicity (e.g. anemia, leukopenia, neutropenia, and thrombocytopenia).
- Increased risk of hematologic toxicity (e.g. anemia, leukopenia, neutropenia, and thrombocytopenia).
Nelarabine
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Nelarabine
Mfr rec avoid breastfeeding; risk of severe neurological reactions in infant
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr rec avoid breastfeeding; risk of severe neurological reactions in infant |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Nelarabine
Neuro/Psych-Increasing age, especially >64 is associated with increased rates of neurological ADRs.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Infrequently, serious nervous system problems have occurred with the use of this medication. The risk may be increased if you have previously received chemotherapy injection into a certain part of the spine (intrathecal) or radiation treatment to the head/spine area. Tell your doctor right away if you notice any symptoms of nervous system problems including: extreme sleepiness, confusion, numbness/tingling in hands/feet, loss of coordination, muscle weakness, or unsteadiness while walking.<br /><br />Seek immediate medical attention if any of the following symptoms occur: inability to move (paralysis), seizure. These symptoms may not go away completely even when treatment with nelarabine is stopped. Consult your doctor for details.
| T-cell acute lymphoblastic leukemia | |
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
| T-cell lymphoblastic lymphoma | |
| C83.5 | Lymphoblastic (diffuse) lymphoma |
| C83.50 | Lymphoblastic (diffuse) lymphoma, unspecified site |
| C83.51 | Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck |
| C83.52 | Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes |
| C83.53 | Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes |
| C83.54 | Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb |
| C83.55 | Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb |
| C83.56 | Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes |
| C83.57 | Lymphoblastic (diffuse) lymphoma, spleen |
| C83.58 | Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites |
| C83.59 | Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites |
| 0-9 | A-Z |
|---|---|
| C83.5 | Lymphoblastic (diffuse) lymphoma |
| C83.50 | Lymphoblastic (diffuse) lymphoma, unspecified site |
| C83.51 | Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck |
| C83.52 | Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes |
| C83.53 | Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes |
| C83.54 | Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb |
| C83.55 | Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb |
| C83.56 | Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes |
| C83.57 | Lymphoblastic (diffuse) lymphoma, spleen |
| C83.58 | Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites |
| C83.59 | Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites |
| C91.0 | Acute lymphoblastic leukemia [ALl] |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
Formulary Reference Tool